Patents by Inventor Venkitasamy Kesavan
Venkitasamy Kesavan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220403377Abstract: The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a lipophilic moiety. e.g., cholesterol, is is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.Type: ApplicationFiled: March 17, 2022Publication date: December 22, 2022Inventors: Muthiah MANOHARAN, Venkitasamy KESAVAN, Kallanthottathil RAJEEV
-
Patent number: 11312957Abstract: The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a lipophilic moiety. e.g., cholesterol, is is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.Type: GrantFiled: July 26, 2019Date of Patent: April 26, 2022Assignee: Alnylam Pharmaceuticals, Inc.Inventors: Muthiah Manoharan, Venkitasamy Kesavan, Kallanthottathil Rajeev
-
Patent number: 10676740Abstract: The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a lipophilic moiety. e.g., cholesterol, is is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.Type: GrantFiled: February 27, 2018Date of Patent: June 9, 2020Assignee: Alnylam Pharmaceuticals, Inc.Inventors: Muthiah Manoharan, Venkitasamy Kesavan, Kallanthottathil Rajeev
-
Publication number: 20190345498Abstract: The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a lipophilic moiety. e.g., cholesterol, is is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.Type: ApplicationFiled: July 26, 2019Publication date: November 14, 2019Inventors: Muthiah MANOHARAN, Venkitasamy KESAVAN, Kallanthottathil RAJEEV
-
Publication number: 20180258427Abstract: The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a lipophilic moiety. e.g., cholesterol, is is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.Type: ApplicationFiled: February 27, 2018Publication date: September 13, 2018Inventors: Muthiah MANOHARAN, Venkitasamy KESAVAN, Kallanthottathil RAJEEV
-
Patent number: 9453222Abstract: This invention relates composition and methods for making and using chemically modified oligonucleotides agents for inhibiting gene expression.Type: GrantFiled: December 24, 2014Date of Patent: September 27, 2016Assignee: ALNYLAM PHARMACEUTICALS, INC.Inventors: Muthiah Manoharan, Venkitasamy Kesavan, Kallanthottathil G. Rajeev
-
Publication number: 20160264968Abstract: The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a lipophilic moiety. e.g., cholesterol, is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.Type: ApplicationFiled: June 1, 2016Publication date: September 15, 2016Inventors: Muthiah MANOHARAN, Venkitasamy Kesavan, Kallanthottathil Rajeev
-
Patent number: 9394540Abstract: The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a lipophilic moiety. e.g., cholesterol, is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.Type: GrantFiled: May 19, 2014Date of Patent: July 19, 2016Assignee: ALNYLAM PHARMACEUTICALS, INC.Inventors: Muthiah Manoharan, Venkitasamy Kesavan, Kallanthottathil Rajeev
-
Publication number: 20150191726Abstract: This invention relates composition and methods for making and using chemically modified oligonucleotides agents for inhibiting gene expression.Type: ApplicationFiled: December 24, 2014Publication date: July 9, 2015Inventors: Muthiah MANOHARAN, Venkitasamy KESAVAN, Kallanthottathil G. RAJEEV
-
Patent number: 8957223Abstract: This invention relates composition and methods for making and using chemically modified oligonucleotides agents for inhibiting gene expression.Type: GrantFiled: October 19, 2012Date of Patent: February 17, 2015Assignee: Alnylam Pharmaceuticals, Inc.Inventors: Muthiah Manoharan, Venkitasamy Kesavan, Kallanthottathil G. Rajeev
-
Publication number: 20140316124Abstract: The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a lipophilic moiety. e.g., cholesterol, is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.Type: ApplicationFiled: May 19, 2014Publication date: October 23, 2014Inventors: Muthiah MANOHARAN, Venkitasamy KESAVAN, Kallanthottathil RAJEEV
-
Patent number: 8796436Abstract: The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a lipophilic moiety. e.g., cholesterol, is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.Type: GrantFiled: March 22, 2013Date of Patent: August 5, 2014Assignee: Alnylam Pharmaceuticals, Inc.Inventors: Muthiah Manoharan, Venkitasamy Kesavan, Kallanthottathil Rajeev
-
Patent number: 8507661Abstract: The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a lipophilic moiety. e.g., cholesterol, is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.Type: GrantFiled: February 26, 2010Date of Patent: August 13, 2013Assignee: Alnylam Pharmaceuticals, Inc.Inventors: Muthiah Manoharan, Venkitasamy Kesavan, Kallanthottathil G. Rajeev
-
Patent number: 8470988Abstract: The present invention provides single-stranded and double-stranded oligonucleotides comprising at least one aralkyl ligand that improvise the pharmacokinetic properties of the oligonucleotide. The aralkyl ligands of the present invention include naproxen, ibuprofen, and derivatives thereof. The present invention also provides method for modulating gene expression using the modified oligonucleotide compounds and compositions comprising those modified oligonucleotides.Type: GrantFiled: October 23, 2009Date of Patent: June 25, 2013Assignee: Alnylam Pharmaceuticals, Inc.Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Venkitasamy Kesavan
-
Patent number: 8404862Abstract: This invention relates composition and methods for making and using chemically modified oligonucleotides agents for inhibiting gene expression.Type: GrantFiled: July 2, 2009Date of Patent: March 26, 2013Assignee: Alnylam Pharmaceuticals, Inc.Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Venkitasamy Kesavan
-
Patent number: 8017763Abstract: This invention relates composition and methods for making and using chemically modified oligonucleotides agents for inhibiting gene expression.Type: GrantFiled: September 17, 2009Date of Patent: September 13, 2011Assignee: Alnylam Pharmaceuticals, Inc.Inventors: Muthiah Manoharan, Venkitasamy Kesavan, Kallanthottathil G. Rajeev
-
Publication number: 20110082157Abstract: The invention relates to 5-HT receptor antagonists. Novel piperidinylamino-thieno [2,3-d] pyrimidine compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as pulmonary arterial hypertension, migraine, hypertension, disorders of the gastrointestinal tract, restenosis, asthma, obstructive airway disease, prostatic hyperplasia and priapism, anxiety, depression, schizophrenia, neural injury and stroke. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also provided.Type: ApplicationFiled: June 8, 2010Publication date: April 7, 2011Inventors: Dale S. Dhanoa, Oren Becker, Silvia Noiman, Sekar A. Reddy, Srinivasa Rao Cheruku, Rosa E. Mele'ndez, Anurag Sharadendu, Dongli Chen, Yael Marantz, Sharon Shacham, Alexander Heifetz, Boaz Inbal, Venkitasamy Kesavan, Shay Bar-Haim
-
Publication number: 20100292455Abstract: The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a lipophilic moiety. e.g., cholesterol, is is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.Type: ApplicationFiled: February 26, 2010Publication date: November 18, 2010Applicant: ALNYLAM PHARMACEUTICALSInventors: Muthiah MANOHARAN, Venkitasamy KESAVAN, Kallanthottathil G. RAJEEV
-
Patent number: 7745608Abstract: The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a lipophilic moiety. e.g., cholesterol, is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.Type: GrantFiled: August 10, 2004Date of Patent: June 29, 2010Assignee: Alnylam Pharmaceuticals, Inc.Inventors: Muthiah Manoharan, Venkitasamy Kesavan, Kallanthottathil G. Rajeev
-
Publication number: 20100113485Abstract: The invention relates to 5-HT receptor modulators, particularly 5-HT2B antagonists. Novel piperidinylamino-thieno[2,3-d]pyrimidine compounds represented by Formula I, II and III, and uses thereof for treating conditions including pulmonary arterial hypertension, congestive heart failure, and hypertension.Type: ApplicationFiled: October 30, 2009Publication date: May 6, 2010Inventors: Dale S. Dhanoa, Oren Becker, Silvia Noiman, Sekar Reddy Alla, Srinivasa Rao Cheruku, Rosa E. Mele'ndez, Anurag Sharadendu, Dongli Chen, Yael Marantz, Sharon Shacham, Alexander Heifetz, Boaz Inbal, Venkitasamy Kesavan, Shay Bar-Haim